Pharma giants seek closure on COVID-19 vaccine rows
Regeneron inks deal over suit concerning a protein for testing COVID-19 treatments | BioNTech aims to resolve university dispute over patented tech used in the Comirnaty vaccine.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
8 October 2024 Judge says use of patented protein mNeonGreen not covered by Section 271(e)(1) provision I Allele granted summary judgment in patent infringement suit.
8 October 2024 Judge says use of patented protein mNeonGreen not covered by Section 271(e)(1) provision I Allele granted summary judgment in patent infringement suit.
8 October 2024 Judge says use of patented protein mNeonGreen not covered by Section 271(e)(1) provision I Allele granted summary judgment in patent infringement suit.